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Purpose. To assess neurocognitive function (NCF), psychosocial outcome, health-related quality of life (HRQoL), and long-term
effects of immune-related adverse events (irAE) on metastatic melanoma survivors treated with ipilimumab (IPI). Methods.
Melanoma survivors were identified within two study populations (N = 104), at a single-center university hospital, and defined
as patients who were disease-free for at least 2 years after initiating IPI. Data were collected using 4 patient-reported outcome
measures, computerized NCF testing, and a semistructured interview at the start and 1-year follow-up. Results. Out of 18 eligible
survivors, 17 were recruited (5F/12M); median age is 57 years (range 33-86); and median time since initiating IPI was 5.6 years
(range 2.1-9.3). The clinical interview revealed that survivors suffered from cancer-related emotional distress such as fear of
recurrence (N = 8), existential problems (N = 2), survivor guilt (N = 2), and posttraumatic stress disorder (N = 6). The mean
EORTC QLQ-C30 Global Score was not significantly different from the European mean of the healthy population. Nine
survivors reported anxiety and/or depression (Hospitalization Depression Scale) during the survey. Seven survivors (41%)
reported fatigue (Fatigue Severity Scale). Seven patients (41%) had impairment in NCF; only three out of seven survivors had
impairment in subjective cognition (Cognitive Failure Questionnaire). Anxiety, depression, fatigue, and neurocognitive
symptoms remained stable at the 1-year follow-up. All cases of skin toxicity (N = 8), hepatitis (N = 1), colitis (N = 3), and
sarcoidosis (N = 1) resolved without impact on HRQoL. Three survivors experienced hypophysitis; all suffered from persistent
fatigue and cognitive complaints 5 years after onset. One survivor who experienced a Guillain-Barré-like syndrome suffered
from persisting depression, fatigue, and impairment in NCF. Conclusion. A majority of melanoma survivors treated with IPI
continue to suffer from emotional distress and impairment in NCF. Timely detection in order to offer tailored care is
imperative, with special attention for survivors with a history of neuroendocrine or neurological irAE. The trial is registered
with B.U.N. 143201421920.
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1. Introduction
Until 2010, no treatment option had improved overall sur-
vival (OS) in patients with metastatic melanoma. Since then,
effective life-prolonging systemic therapies have been
approved of which ipilimumab (IPI), a monoclonal antibody
that blocks the cytotoxic T-lymphocyte-associated antigen 4
(CTLA-4) immune checkpoint receptor, was the first. Across
studies, treatment with IPI increases the percentage of long-
term survival (>3 years) by 10 to 15% [1].
Unfortunately, IPI is also associated with a range of
immune-related adverse events (irAE) such as rash, diarrhea,
colitis, hepatitis, hypophysitis, and fatigue occurring both
during or even after treatment termination [2]. Most of these
irAEs are reversible, with the exception of some endocrine
and neurological side effects [3]. Given that modulation of
immune and endocrine systems also impacts on the normal
function of the central nervous system (CNS), immune
checkpoint blockade has the potential to give rise to neuro-
psychiatric symptoms such as depressive mood, anxiety,
and impairment in neurocognitive function [4]. Despite this
potential, little is known about the long-term effects of
immune checkpoint inhibitors (ICI) on neuropsychiatric
symptoms in individuals with metastatic melanoma [1].
As many patients with advanced melanoma discontinue
their ICI therapy and become long-term cancer survivors,
the issue of melanoma survivorship care gains importance
[5, 6]. In the field of melanoma, the psychosocial outcome
and health-related quality of life (HRQoL) have been studied
mainly in individuals with early-stage disease [1]. In these
survivors, due to the risk of developing recurrence of mela-
noma, there is a necessity for continued self-examination,
regular dermatological control visits, and reduced sun expo-
sure [7]. Such prevention measures can themselves increase
anxiety as well as fear of recurrence, causing denial behavior
and leading to decreased self-examination and avoidance of
dermatological control visits [8]. The often highly traumatic
course of metastatic melanoma may also contribute to
greater difficulty in coping when compared to other cancer
indications [9].
Studies of psychosocial outcomes in metastatic mela-
noma survivors are scarce, but all report diminished HRQoL
and high levels of distress [10]. Therefore, the aim of this pro-
spective study was to assess the HRQoL and psychosocial and
neurocognitive outcomes as well as to document possible
sequelae of irAE in survivors of metastatic melanoma treated
with IPI. In line with previous findings, the hypothesis was
that the first generation of IPI survivors is at high risk of
developing emotional distress.
2. Methods
This single-center study was undertaken at the Universitair
Ziekenhuis Brussel, Brussels, Belgium. Patients were
recruited from two prospective studies (ClinicalTrials.gov:
NCT02673970 and NCT01302496). This substudy investi-
gating HRQoL and psychosocial and neurocognitive out-
comes was approved by the institutional Ethical Committee
in 2016 (B.U.N. 143201421920). All patients provided writ-
ten informed consent.
2.1. Study Population. Survivors were recruited by reviewing
the databases of the prospective studies. Eligible patients
were aged 18 or over, with an unresectable stage IIIC or IV
melanoma; survivors were disease-free for at least 2 years fol-
lowing the start of IPI and with no subsequent treatment for
their metastatic melanoma.
2.2. Procedures. Survivors were contacted by phone and
invited to participate. After consenting, they could make an
appointment to perform the baseline assessment, defined as
T0, including a clinical interview (60 minutes); completion
of patient-reported outcome measures (PROMs) assessing
fatigue, HRQoL, anxiety, depression, and impairment in sub-
jective cognitive function (30 minutes); and objective assess-
ment of neurocognitive function (NCF), measured by the
Cogstate test battery (40 minutes). All questionnaires were
checked for incompleteness, and patients were asked to com-
plete the missing items. Sociodemographic and clinical data
were collected from the parental prospective study and a
standardized questionnaire.
The baseline assessment took place outside the oncologi-
cal visits, so as to avoid bias related to distress of the medical
control visit. A follow-up assessment was planned one year
after baseline, defined as T1, and comprised the PROMs
and the objective assessment of NCF.
Treatment-related toxicity of IPI and adverse events
related to adjuvant therapy were documented from the
parental prospective studies.
2.3. Semistructured Clinical Interview. At the baseline assess-
ment, a semistructured clinical interview was performed by
the first author, an experienced psychiatrist in the field of
psychooncology. The interview started with the open-ended
question on how diagnosis of metastatic melanoma had been
announced and what emotions the survivors felt at that
moment. Thereafter, a semistructured clinical interview
(SCID-IV-CV) based on the Diagnostic and Statistical Man-
ual (DSM-IV-R) was administered to establish a psychiatric
diagnosis [11]. Notes of the psychiatric interview were filled
in a standardized form. The purpose of this clinical interview
was to have additional clinical information to that provided
by the PROMs and to assess whether emotional distress
was cancer-related. The interview ended with two open-
ended questions about the level of fear of cancer recurrence
and the degree of uncertainty.
2.4. Patient-Reported Outcome Measures
2.4.1. Health-Related Quality of Life. The European Organi-
zation for Research and Treatment of Cancer Quality of Life
Questionnaire C30 (EORTC QLQ-C30) is a PROM that
assesses HRQoL in cancer patients [12]. Taking into account
that survivors included in this study had to be disease-free
and without cancer treatment for at least 2 years after ini-
tiation of IPI, we considered it appropriate to compare
mean scores of our survivor population with the European
mean of the healthy population. The EORTC QLQ-C30 is
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composed of 30 items, consisting of 5 functional dimensions
(physical, emotional, role, cognitive, and social functioning),
9 symptomatic dimensions (fatigue, nausea/vomiting, pain,
dyspnea, insomnia, appetite loss, constipation, diarrhea, and
financial impact), which are all scored on a 4-point Likert
scale, and one dimension of global HRQoL, measured by 2
items, each scored on a 7-point Likert scale. According to
the guidelines, a linear transformation was used to standardize
the raw scores from 0 to 100. Differences in scores were con-
sidered as clinically relevant according to the guidelines for
interpretation of longitudinal HRQoL differences [13].
Thresholds for clinical importance of the EORTC QLQ-C30
were calculated based on the data from Griesinger et al. [14].
2.4.2. Anxiety and Depression. The Hospitalization Anxiety
and Depression Scale (HADS) is a 14-item self-report scale,
7 assessing anxiety and 7 depression on a 4-point Likert
scale [15]. The HADS has been validated in Dutch and
French [16, 17]. A cutoff score of ≥8 has been validated as
clinically important to assess emotional distress in oncolog-
ical settings [18].
2.4.3. Fatigue. The Fatigue Severity Scale (FSS) is a 9-item
self-report instrument, on a 7-point Likert scale with scores
of ≥4 indicating moderate fatigue [19]. The FSS is validated
in Dutch and French [20, 21].
2.4.4. Subjective Cognition. The Cognitive Failure Question-
naire (CFQ) is a 25-item self-report scale, on a 5-point Likert
scale [22]. The CFQ measures impairment in subjective cog-
nitive function with scores ≥ 44 indicating impairment in
subjective cognition and scores ≥ 55 indicating severe
impairment in subjective cognition. The CFQ is validated
in Dutch and French [23, 24].
2.5. Neurocognitive Function. Neurocognitive function
(attention, memory, and executive function) was measured
by the objective tests from the Cogstate battery, evaluating
processing speed; detection test (DET), attention; identifica-
tion test (IDN), verbal memory; International Shopping List
(ISL) and International Shopping List Delay (ISRL), working
memory; One Back test (ONB); and executive function
GrotonMaze Learning Test (GMLT). The following compos-
ite cognitive functions were defined: memory processing
speed compound (IDN, DET), memory compound (ISL,
ISLR, and ONB), and executive function compound (GMLT,
ONB). The Cogstate test battery is validated in the oncologi-
cal setting [25]. For each survivor, performance on each test
was standardized using age-matched normative data [26].
Impairment on a single test was classified when performance
was lower than 1 standard deviation below normal age-
appropriate mean. Impairment in NCF for an individual
was classified when abnormal performance occurred on at
least 3 tests of the 7 in the battery according to the guidelines
of the International Cognition and Cancer Task Force rec-
ommendations [27].
2.6. Statistical Analysis. Descriptive statistical analysis was
performed using Jamovi (v1.1.7.0) and R3.6.1. Results were
considered significant at an alpha level of 0.05 two-sided.
Norm-based data of the EORTC-QLQ_C30 from the
European Healthy population were compared with the
HRQoL outcomes of the study population using one-
sample t-tests [28].
3. Results
3.1. Study Population.Of 104 IPI-treated patients considered,
18 survivors (5F/13M), with a median age of 57 years (range
33-86), were eligible, and of these candidates, 17 consented to
participate. At baseline assessment (T0), median time since
starting IPI treatment was 5.6 years (range 2.1-9.3) and
median time since complete remission or best overall
response of metastatic disease was 4 years (range 1.6 to
6.3). Patient characteristics at baseline (T0) are summarized
in Table 1. Fifteen survivors completed the one-year follow-
up assessment (T0): one survivor became ineligible for fur-
ther assessment due to progression of previously diagnosed
prostate cancer, and one survivor had a recurrence of meta-
static melanoma. Both patients were in complete remission
at study entry (respectively, 1.8 years and 5.2 years). Ipilimu-
mab administration, date of complete remission, data collec-
tion, and adverse events of special interest are shown in
Figure 1.
3.2. Immune-Related Adverse Events. Immune-related
adverse events (irAE) were retrieved from the databases of
the parental prospective studies. Three patients developed
hypophysitis, of whom two were subsequently referred for a
psychiatric consultation (respectively, 10 and 3 months after
the incidence of hypophysitis). The first patient suffered from
obsessive-compulsive disorder (OCD) with comorbid
depressive disorder and suicidal ideation. The second patient
was referred for depressive symptoms, cognitive distur-
bances, fatigue, and suicidal ideation (Figure 2). The third
patient consulted an external psychologist for anxiety and
depressive symptoms with suicidal ideation without further
follow-up. Only the first patient had a history of a depressive
episode, 8 years before diagnosis of melanoma, successfully
treated with antidepressants.
All three survivors were treated with a physiological
substitution dose of hydrocortisone. The first survivor also
remained in need of thyroid and growth hormone substi-
tution and continued to suffer from obsessive compulsive
disorder with comorbid depression, severe fatigue, and
arthralgia as well as impairment in NCF at baseline line
and follow-up assessment. For the second survivor, we
found impairment in NCF at baseline and follow-up
assessment; depression related to the hypophysitis was
resolved at baseline (case illustration Figure 2). The third
survivor suffered from persisting cancer-related posttrau-
matic stress disorder (PTSD) at baseline. The patient-
reported outcomes (PROs) revealed that all three suffered
from persisting fatigue (FSST0 scores = 6; 4 and 4), anxiety
(HADS‐AT0 scores = 10; 9 and 8), depressive symptoms
(HADS‐DT0 scores = 10; 9 and 8), and impairment in subjec-
tive cognition (CFQT0 scores = 66; 47 and 50) at baseline and
at one-year follow-up assessment: fatigue (FSST1 scores = 6; 4
and 5), anxiety (HADS‐AT1 scores = 19; 9 and 8), depressive
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symptoms (HADS‐DT1 scores = 14; 4 and 9), and impair-
ment in subjective cognition (CFQT1 scores = 72; 45 and 50).
One survivor developed a grade 4 sensorimotor poly-
neuropathy (Guillain-Barré-like syndrome) that was
reported elsewhere [29]. Assessment of PROs reports fatigue
(FSST0 = 5, T1 = 4), anxiety and depression (HADS‐AT0 = 9,
T1 = 12; HADS‐DT0 = 8, T1 = 13), and severe impairment
in subjective cognition (CFQ at T0 = 70, T1 = 79). Assess-
ment of NCF revealed a general impairment in NCF at
baseline and at one-year follow-up. According to the
SCID-IV-CV, the survivor suffered from a major depressive
disorder.
All cases of immune-related skin toxicity (8 patients),
hepatitis (1 patient), colitis (3 patients), and sarcoidosis
(1 patient), as well as the Guillain-Barré-like syndrome
(1 patient) recovered completely. Table 2 gives an overview
of all irAE.
As for non-immune-related long-term toxicity, one sur-
vivor suffered from lymphedema related to the resection of
Table 1: Baseline characteristics of the study population.
N = 17 (100%)
Sex
Male 5 (29%)
Median age in years (range) 63.4 (42-85)
Demographics
Education
Low (junior high school) 5 (29%)
Intermediate (senior high school) 7 (41%)
High (graduate bachelor or master) 5 (29%)
Work situation
Work 6 (35%)
Sick leave 3 (18%)
Retired 8 (47%)
Marital status
Married/cohabitation with partner 12 (71%)
Divorced/separated 2 (12%)
Widowed 2 (12%)
Single/never married 1 (6%)
Children
Young children (0-21 yrs) 5 (29%)
Adult children (≥21 yrs) 10 (59%)
No children 2 (12%)
Psychiatric history
Depression 1 (6%)
No psychiatric history 15 (88%)
Psychotropic treatment
Antidepressant 2 (12%)
Hypnotic benzodiazepine 3 (18%)
ECOG performance status
0 7 (41%)
1 5 (29%)
2 5 (29%)
Treatment
Previous treatment before ipilimumab
Chemotherapy 9 (53%)
BRAF/MEK inhibitors 1 (6%)
Study drug (IFN or TriMixDC-MEL) 7 (41%)
Radiotherapy
9 (53%) non-CNS, 1
(6%) CNS
Surgery 2 (12%)
Therapy during ipilimumab treatment
Radiotherapy 2 (12%)
Surgery 2 (12%)
Retreatment with ipilimumab after
interruption
3 (18%)
Dose of ipilumumab per administration
3mg/kg 8 (47%)
10mg/kg 9 (53%)
Survival
17 (100%)
Table 1: Continued.
N = 17 (100%)
Number of patients disease-free and
without any cancer treatment at baseline∗
Median time since starting ipilimumab
at baseline in years (range)
5.6 (2.1-9.3)
Median time since stopping
ipilimumab at baseline in years (range)
4.0 (1.9–8.6)
Median time since complete remission
or best overall response at baseline in
years (range)
4.0 (1.6–8.6)
Number of patients who completed the
1-year follow-up assessment
15 (88%)
Melanoma
Median time to diagnosis of stages
IIIC-IV in years (range)
6.8 (3.4-12.1)
Location of primary tumor
Head 3 (18%)
Neck 1 (6%)
Trunk 4 (24%)
Upper extremity 2 (12%)
Lower extremity 4 (24%)
Unknown 3 (18%)
AJCC TNM stage 8th edition
IIIC 2 (12%)
IV-M1a 1 (6%)
IV-M1b 7 (41%)
IV-M1c 6 (35%)
IV-M1d 1 (6%)
∗One survivor obtained a complete metabolic response on 18F-FDG/PET
and a partial response on CT scan; 1 survivor obtained a stable disease
both on 18F-FDG/PET and CT scan; 15 survivors obtained a complete
response, defined as the absence of any abnormality on whole-body 18F-
FDG PET/CT.
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the axillar lymph nodes and one had a partial gastrectomy
for gastric metastasis.
3.3. Semistructured Clinical Interview. The clinical interview
revealed that all survivors reported fear of cancer recurrence
(FCR) and feelings of uncertainty. Nine pts (53%) reported
persisting emotional distress: existential problems (N = 2),
survivor guilt (N = 2), or daily worrying about melanoma
recurrence (N = 8). Six survivors were classified with
cancer-related PTSD (35%) and two survivors with major
depressive disorder. The following stressors were reported
as life-threatening: rapid disease progression with respiratory
distress related to compression of the upper airway by medi-
astinal lymph node metastases (N = 1) and announcement of
a diagnosis of inevitably incurable disease with short life
expectancy (N = 4), and in one survivor, this was related to
an acute Addison crisis in the context of a grade 4 hypophy-
sitis (Figure 2). In 8 survivors (47%), no major cancer-related
problems were identified.
3.4. Patient-Reported Outcomes
3.4.1. Health-Related Quality of Life. At baseline, the mean
EORTC QLQ-C30 Global Score was not significantly differ-
ent from the European mean of the healthy population
[28]. Mean scores for cognitive function were significantly
lower than their relevant healthy population means, indicat-
ing greater impairment. Survivors had no significantly higher
symptom level compared to the European mean of healthy
subjects [28]. When looking at individual thresholds for clin-
ical importance, we found that 6 survivors (35%) suffered
from fatigue and 5 survivors (29%) from impaired emotional
function at baseline and at one-year follow-up [14]. Seven
patients had no clinically important dysfunction or symptom
levels. At the one-year follow-up, one survivor had a clinical
improvement of the global HRQoL score (with 17 points),
and two worsened (both with 33 points). Table 3 shows the
descriptive statistics of the EORTC QLQ-C30 scores.
3.4.2. Anxiety and Depression. At the baseline and one-year
follow-up, a total of 9 survivors (53%) reported clinical levels
of anxiety and/or depressive symptoms (HADS ≥ 8). At the
baseline, 6 survivors (35%) suffered from anxiety and 7
(41%) from depressive symptoms, whereas 5 (30%) had
clinical levels of both anxiety and depressive symptoms. All
survivors with clinical levels of anxiety at the baseline had
persistent anxiety symptoms at one-year follow-up assess-
ment. Details are illustrated in Table 4.
3.4.3. Fatigue. Seven survivors (41%) suffered from fatigue
according to the FSS (≥4) at the baseline, and all of these
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Figure 1: Swimmer plot illustrating duration of IPI administration, date of complete remission (CR), date of stable disease (SD), time of
baseline assessment and follow-up, and irAE of special interest. For 2 survivors, no assessment was available at one-year follow-up: one
died (†) and one had recurrence of metastatic melanoma (∗).
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continued to suffer from fatigue at the one-year follow-up
(Table 4).
3.4.4. Subjective Cognition. Seven survivors suffered from
impairment in subjective cognition (CFQ ≥ 44) of whom
four had scores ≥ 55, indicating severe impairment in subjec-
tive cognition (Table 4). Impairment in subjective cognition
persisted for all survivors at the one-year follow-up. Six of
the seven survivors with impairment in subjective cognition
also had persisting high levels of fatigue. The one survivor
who developed a brain metastasis (treated with radiother-
apy), nine years before baseline assessment, did not have
elevated CFQ scores at either baseline or one-year follow-up.
3.5. Correlations. Anxiety and depression (HADS), fatigue
(FSS), subjective cognition (CFQ), and emotional and cogni-
tive function of HRQoL (EORTC QLQC30) were highly
correlated at baseline and at one-year follow-up (Table 5).
3.6. Neurocognitive Function. Data from neurocognitive test-
ing was available for 16 survivors; one survivor of 85 years
declined assessment for personal reasons. At baseline, seven
(44%) survivors had impairment in NCF as defined in the
protocol. At the z ≤ −1:00 cutoff, 10 patients (62%) were
impaired on 2 or more tests. At the one-year follow-up,
neurocognitive data were available for 12 survivors of which
four (33%) were classified with impairment in NCF; for two
survivors with impairment in NCF at baseline, no assessment
was available at one-year follow-up. Mean scores are shown
in Table 4. Four of the seven survivors with impairment in
NCF had no impairment in subjective cognition. The survi-
vor with a history of brain metastasis had no impairment in
NCF neither in subjective cognition (CFQ) at baseline and
at one-year follow-up. Of the individual tests, only perfor-
mance on the verbal memory test (ISLT) was correlated
significantly with ratings of fatigue (FSS), anxiety and depres-
sion (HADS), and subjective cognition (CFQ).
3.7. Overview of Results across Measures. The clinical inter-
view revealed that 8 survivors with a good emotional coping
did globally very well and had no elevated scores on the
HADS, CFQ, and EORTC global and functional scales.
Within this group, one survivor reported persisting fatigue,
which was confirmed by elevated scores on the FSS and the
200
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Figure 2: Case illustration. Sagittal section of a gadolinium-enhanced magnetic resonance image from a patient who developed acute
symptomatic immune-related hypophysitis leading to an isolated insufficiency of the corticotropic axis. The patient had an Addison crisis
three weeks after the fourth administration of IPI (cumulative dose 1080mg). The MRI image reveals a diffusely swollen and gadolinium-
enhanced pituitary gland with a hypointense lesion in the right adenohypophysis and thickening of the stalk. Laboratory findings showed
undetectable ACTH levels at the time of diagnosis. The patient was diagnosed with posttraumatic stress disorder (PTSD) related to the
symptoms of an Addison crisis with comorbid depressive mood, fatigue, suicidal ideation, psychomotor retardation, and severe subjective
neurocognitive symptoms. After one year of psychiatric follow-up, the patient recovered from depression and PTSD; however, he had a
recurrence of depression two years later due to fear of recurrence, which again was successfully treated after psychiatric intervention.
Table 2: Overview of immune-related adverse events (IrAEs).
Grade
Number of
IrAE
Intervention
Hypophysitis 3-4 3 Methylprednisolone
Maculopapular
rash
1-2 4
Steroid local skin
application
Dry skin 2 2 —
Pruritus 1-2 5 Antihistaminic
Diarrhea 1-2 7 —
Colitis 3 4 Methylprednisolone
Hepatitis 3 1 Methylprednisolone
Pneumonitis 3 1 Methylprednisolone
Flu-like
syndrome
2 2 —
Guillain-Barré 4 1 Methylprednisolone
Sarcoidosis 2 1 Methylprednisolone
Fatigue 2 4 —
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EORTC fatigue symptom subscale. Of the 7 survivors with-
out any complaints, 4 were classified as showing impairment
in NCF.
4. Discussion
In this prospective pilot study, we found that a high number
(38%) of metastatic melanoma survivors treated with IPI
continued to suffer from clinically relevant levels of anxiety,
persisting fatigue, and subjective and objective neurocogni-
tive impairment several years after cessation of IPI treatment.
These findings from the initial assessment in the survivors
were confirmed at a one-year follow-up assessment.
Our preliminary study results showed impairment in
NCF in a large proportion (44%) of survivors. In fact, two
survivors reported having to stop working due to their cogni-
tive impairment that had persisted after recovery of the
disease. The presence of this impairment was confirmed
Table 3: EORTC QLQ-C30 functional and symptom scales at T0 and T1 compared to the pooled European normative data [28].
EORTC QLQ-C30
Mean (SD)
p value
T0
N = 17
Range
Mean (SD)
p value
T1
N = 15
Range
European mean (SD)
N = 15386
Function scales
Physical
84.3 (15.3)
p = 0:83 [47-100]
80.9 (16.3)
p= 0.33
[53-100] 85.1 (18.9)
Role
85.3 (21.2)
p = 0:85 [33-100]
81.1 (18.7)
p = 0:52 [50-100] 84.3 (24.6)
Emotional
79.9 (29.0)
p = 0:43 [0-100]
80.0 (17.5)
p = 0:22 [50-100] 74.2 (24.7)
Cognitive
72.6 (27.6)
p = 0:09 [0-100]
64.4 (25.9)
p = 0:009
d = 0:79
[17-100] 84.8 (21.3)
Social
85.3 (21.2)
p = 0:86 [33-100]
77.8 (25.7)
p = 0:23 [33-100] 86.2 (24.1)
Global QOL
76.0 (17.4)
p = 0:03
d = 0:47
[50-100]
72.2 (22.9)
p = 0:33 [42-100] 66.1 (21.7)
Symptom scales/items
Fatigue
27.5 (25.8)
p = 0:75 [0-78]
21.5 (20.4)
p = 0:15 [0-67] 29.5 (25.5)
Nausea/vomiting
2.0 (5.5)
p = 0:01
d = 0:59
[0-17]
5.6 (15.0)
p = 0:93 [0-50] 5.9 (16.0)
Pain
12.7 (16.2)
p = 0:01
d = 0:57
[0-33]
18.9 (23.5)
p = 0:46 [0-67] 23.5 (27.1)
Dyspnea
13.7 (29.0)
p = 0:76 [0-100]
15.6 (24.8)
p = 0:96 [0-67] 15.9 (24.6)
Insomnia
11.8 (16.4)
p = 0:002
d = 0:68
[0-33]
13.3 (21.1)
p = 0:03
d = 0:63
[0-67] 26.6 (30.3)
Appetite loss
7.8 (18.7)
p = 0:64 [0-67]
15.6 (33.0)
p = 0:53 [0-100] 10.0 (21.6)
Constipation
5.9 (17.6)
p = 0:14 [0-67]
9.0 (23.4)
p = 0:57 [0-67] 12.5 (23.3)
Diarrhea
11.8 (20.2)
p = 0:65 [0-67]
6.7 (13.8)
p = 0:45 [0-33] 9.5 (20.9)
Financial difficulties
13.7 (33.5)
p = 0:71 [0-100]
13.4 (24.7)
p = 0:67 [0-67] 10.6 (23.6)
Bilateral one sample t-tests have been conducted to compare the means with the normative data of the pooled European normative data. d = Cohen’s d
effect size (0.2 = small effect, 0.5 =medium effect, and 0.8 = large effect). Functional scales: a lower score compared to the European mean indicates a worse
functioning. Symptom scales: a higher score compared to the European mean indicates more symptoms.
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through application of the objective cognitive assessments.
The large proportion of survivors with impairment in NCF
could be consistent with the study results of Bartels et al.,
who found that neuronal autoantibodies can provoke neuro-
cognitive impairment, assessed with objective testing in
approximately 20% of melanoma patients during treatment
(N = 157), and that seropositivity of neuronal autoantibodies
was also associated with ICI treatment [30]. However, to our
knowledge, there are no data available on the influence of
cognition, measured objectively, in survivors previously
treated with ICI.
Of interest was that impairment in NCF did not accord
with impairment in subjective cognition in more than half
of the objectively impaired survivors (4/7). Impairment in
subjective cognition was associated more strongly with levels
of fatigue, anxiety, and depressive symptoms. The high
proportion of survivors with impairment in NCF as well as
the discrepancy between impairment in subjective cognition
and impairment in NCF is also consistent with our previous
observations made in short-termmetastatic melanoma survi-
vors (in remission since 6 months) treated with the anti-PD1
immune checkpoint inhibitor, pembrolizumab [31].
The occurrence of mood disorders during hypophysitis
and neurological irAE might raise the question of whether
depression and neurovegetative symptoms should be consid-
ered as immune-related adverse events. The current results
draw attention to the importance of closely monitoring
suicidal ideation as this occurred in all three cases of hypo-
physitis. Of clinical interest is that in none of these cases,
suicidal ideation was reported spontaneously by the patients
to their treating oncologist. Our results suggest that the
occurrence of neurotoxicity and neuroendocrinological
irAEs could potentially have long-term neuropsychiatric
and neurovegetative consequences in humans. This sugges-
tion is consistent with the complex interactions between
stress, the immune system, the central nervous system, and
the tumor microenvironment described previously in pre-
clinical models [32] [33] [34].
The semistructured clinical psychiatric interview revealed
that metastatic melanoma survivors suffered from persisting
disease-related emotional distress. About half of the survi-
vors (53%) reported fear of cancer recurrence and emo-
tional coping difficulties related to the uncertainty of
surviving a potentially lethal disease with a novel treatment
of which the long-term outcome remained unknown at the
time of the start of this experimental treatment. This is
consistent with the findings of Levy et al. describing the
burden of uncertainty in patients on active ICI treatment
[35]. Posttraumatic stress disorder was present in one-
third of the survivors and was related to the moment of
receiving a diagnosis of incurable cancer, the traumatic
course of disease progression, or the occurrence of irAEs.
This is in accord with our previous findings in short-term
survivors treated with pembrolizumab as well as with the
results of a meta-analysis, where Abbey et al. reported that
cancer diagnosis and treatment can induce PTSD [9, 31].
Younger age, completion of treatment, and more advanced
disease were found to be associated with a higher risk for
developing PTSD [36]. This study population consists of
the first generation of survivors, and the high prevalence
of PTSD can be better understood when considering that
at the time these survivors received their diagnosis, no
curative treatment option was available. However, it is of
interest that a substantial number of survivors (41%)
showed good emotional coping strategies, with no elevated
scores on the HADS, CFQ, FSS, or EORTC QLQ-C30
global and functional scales.
According to the EORTC QLQ-C30, and confirming our
clinical findings, we found reduced HRQoL in cognitive
function. In line with the results on the FSS, HADS, and
CFQ, a high number of survivors presented clinical impor-
tant fatigue symptoms (41%) as well as impaired emotional
function (29%) and cognitive function (41%).
Global HRQoL was not different from the normal popu-
lation. This might be related to the small number of subjects
included in this study or to a response shift, which can be
explained by an adjustment mechanism to a permanently
Table 4: Descriptive statistics of anxiety, depression, fatigue,
subjective and objective cognitive impairment, and number of
patients impaired.
T0
N = 17
T1
N = 15
Anxiety and depression
HADS anxiety (mean, SD) 5.8 (6.0) 6.4 (6.4)
HADS depression (mean, SD) 5.5 (3.4) 5.4 (4.7)
Number of patients (%) with elevated
A scores (≥8) 6 (35%) 6 (40%)
Number of patients (%) with elevated
D scores (≥8) 7 (41%) 4 (27%)
Number of patients (%) with elevated
A and D scores (≥8) 5 (30%) 4 (27%)
Fatigue
FSS (mean, SD) 3.0 (1.8) 3.1 (1.5)
Number of patients (%) with elevated
scores (≥4) 7 (41%) 7 (47%)
Subjective cognition
CFQ (mean, SD) 39.8 (23.1) 40.7 (23.7)
Number of patients (%) with elevated
scores (≥44) 7 (41%) 7 (47%)
Cognitive computerized test
results for processing speed,
memory, and executive function
composites
T0
N = 16^^
Mean (SD)
T1
N = 12^^
Mean (SD)
Processing speed composite
-0.67
(1.00)
-1.20
(0.98)
Memory composite
-0.23
(0.97)
0.03 (0.83)
Executive function composite
-0.31
(0.79)
-0.30
(0.90)
Number (%) of patients impaired on
objective computerized testing^
7 (44%) 4 (33%)
^Cognitive impairment was defined when abnormal performance (z ≤ -1.00)
occurred on at least 3 tests of the 7 in the battery. ^^For, respectively, 1 at T0
and 4 patients at 1-year follow-up, no assessment was available.
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lower level of global function and emotional wellbeing (due
to disease), a well-known phenomenon in HRQoL [37]. In
a large cohort study (N = 91) comparing IPI survivors with
matched controls, Boekhout et al. found decreased physical,
role, cognitive, and social functioning as well as increased
financial difficulties and fatigue symptoms according to the
EORTC QLQ-C30 in IPI survivors [38]. These findings are
in line with two recently published surveys, both reporting
significant ICI toxicity, psychological concerns such as fear
of melanoma recurrence, and impairments in specific
HRQoL domains (emotional, physical, role, and social func-
tioning) [38, 39]. Cognitive function was not assessed with an
objective NCF test battery.
Limitations of our study are the small sample size, which
was anticipated at the start of the study. The number of eligi-
ble survivors (17.3%) was in line with the expected number,
which was based on the results of an updated report of
survival rates of the CA184-014 study and a pooled analysis
of 1861 patients, in which the overall survival rate was
18.2% [40, 41]. Due to its small sample size, our study was
underpowered to detect all possible long-term effects. It is
unlikely that the observations were biased by a high prev-
alence of preexisting psychoemotional disturbances since
such a condition occurred in only one of the studied sur-
vivors. In the absence of a control group, normative data
were used to assess HRQoL, anxiety, and depression. No
causal relationship between IPI treatment and our findings
can be concluded as all survivors were heavily pretreated.
The strengths of this study are the prospective follow-up
design and the combination of PROs with a clinical interview
which allows evaluating whether the complaints of emotional
distress were disease-related or not. An additional strength is
that all survivors achieved long-term remission on IPI for at
least 2 years (median time since remission was 4 years) and
were off treatment for at least 2 years (median time of stop-
ping therapy was 4 years), which might reduce confounding
effects related to pharmacological adverse events or differ-
ences between CTLA-4 inhibitors and other ICI.
4.1. Clinical Implications. Our study results highlight the
need to further address the neurocognitive dysfunction and
psychoemotional needs of a rapidly growing new population
of melanoma survivors treated with immune checkpoint
inhibitors. Special attention to the survivors who suffered
from neuroendocrine and CNS irAE seems to be warranted.
The treatment outcomes could potentially be improved by
offering distress-reducing tailored psychosocial care, which
is an additional incentive for further research in the field of
immunotherapy, especially in view of the use of ICI in the
adjuvant setting as well as in other cancer indications.
4.2. Conclusions. Taken together, the current results suggest
that in survivors of advanced melanoma, there is continued
emotional distress, fatigue, and neurocognitive impairment
with an impact on the HRQoL. Timely detection in order
to offer tailored care is imperative. Even though this is a rel-
atively small sample size, immunotherapy is developing rap-
idly, and therefore, we believe that it is important to
communicate the robust adverse outcomes of our prospec-
tively studied cohort to the field.
Data Availability
Data are available upon request.
Conflicts of Interest
AR reports personal fees from Bristol-Myers Squibb and
Merck Sharp & Dohme, outside the submitted work. GA
and JKS report travel accommodations—Merck Sharp &
Dohme, Pfizer, and Astellas—outside the submitted work.
AS and PM report to be full-time employees of Cogstate
Ltd, the company that provided the computerized cognitive
Table 5
(a) Descriptive statistics and correlations between main variables at baseline (T0)
M (SD) FSS1 Anx2 Dep3 CFQ4 Glob5 CF6 EF7 PF8 RF9 SF10 FA11
FSS1 3.0 (1.8) 0.71∗∗ 0.49∗ 0.76∗∗∗ -0.41 -0.18 -0.66∗∗ -0.25 -0.26 -0.34 0.75∗∗∗
Anx2 5.8 (6.0) 0.30 0.78∗∗∗ -0.48m -0.23 -0.84∗∗∗ -0.29 -0.26 -0.51∗ 0.67∗∗
Dep3 5.5 (3.4) 0.24 -0.24 -0.31 -0.37 -0.28 -54∗ -0.09 0.42
CFQ4 39.8 (23.1) -0.43m -0.51∗ -73∗∗∗ -0.24 -0.10 -0.34 0.78∗∗∗
(b) Descriptive statistics and correlations between main variables at one-year follow-up (T1)
M (SD) FSS1 Anx2 Dep3 CFQ4 Glob5 CF6 EF7 PF8 RF9 SF10 FA11
FSS1 2.9 (1.5) 0.60∗∗ 0.46m 0.73∗∗ -0.04 -0.52∗ -0.49m 0.04 -0.31 -0.29 0.32
Anx2 6.1 (6.1) 0.81∗∗∗ 0.73∗∗∗ -0.32 -0.83∗∗∗ -0.86∗∗∗ 0.10 -0.46m -0.56∗ 0.27
Dep3 4.9 (4.6) 0.66∗∗ -0.68∗∗ -0.91∗∗∗ -0.77∗∗∗ -0.37 -0.73∗∗ -0.65∗∗ 0.3
CFQ4 40.5 (22.2) -0.16 -74∗∗ -0.71∗∗ 0.10 -0.33 -0.39 0.27
Note: m =marginally significant. ∗p < 0:05; ∗∗p < 0:01. diagonal = variances. 1Fatigue Severity Scale; 2HADS Anxiety; 3HADS Depression; 4Cognitive Failure
Questionnaire; 5global HRQoL EORTC QLQ-C30; 6Cognitive Function EORTC QLQ-C30; 7Emotional Function EORTC QLQ-C30; 8Physical Function
EORTC QLQ-C30; 9Role Function EORTC QLQ-C30; 10Social Function EORTC QLQ-C30; 11Symptom Scale EORTC QLQ-C30.
9Journal of Immunology Research
tests in this study. BN reports grants and personal fees from
Novartis, personal fees from Bristol-Myers Squibb, personal
fees from Merck Sharp & Dohme, grants and personal fees
from Pfizer, personal fees from AstraZeneca, and grants
and personal fees from Roche, outside the submitted work.
CL, JL, MD, JC, and PT report no conflict of interest.
Authors’ Contributions
AR conceptualized the study design, performed the data col-
lection, developed the original draft of the manuscript, and
worked on the data analysis and the data interpretation; CL
performed the statistical analysis, assisted with the interpre-
tation of the data, and commented on the manuscript; JL
assisted with the data analysis and commented on the manu-
script; AS and PM assisted in the conceptualization of the
study design and data analysis and commented on the man-
uscript; GA, JKS, and JDC assisted with the data collection
and commented on the manuscript; PT, MDR, and JLB com-
mented on the manuscript; BN conceptualized the study
design, assisted with the data interpretation, and performed
the supervision.
Acknowledgments
We would like to thank the patients and their family for par-
ticipating in this study. This study was supported by the
“Foundation Brugmann.”
References
[1] A. Rogiers, A. Boekhout, J. K. Schwarze, G. Awada, C. U.
Blank, and B. Neyns, “Long-term survival, quality of life, and
psychosocial outcomes in advanced melanoma patients
treated with immune checkpoint inhibitors,” Journal of Oncol-
ogy, vol. 2019, Article ID 5269062, 17 pages, 2019.
[2] M. A. Postow andM. D. Hellmann, “Adverse events associated
with immune checkpoint blockade,” The New England Journal
of Medicine, vol. 378, no. 12, p. 1165, 2018.
[3] D. B. Johnson, D. L. Friedman, E. Berry et al., “Survivorship in
immune therapy: assessing chronic immune toxicities, health
outcomes, and functional status among long-term ipilimumab
survivors at a single referral center,” Cancer Immunology
Research, vol. 3, no. 5, pp. 464–469, 2015.
[4] D. Kovacs, P. Kovacs, N. Eszlari, X. Gonda, and G. Juhasz,
“Psychological side effects of immune therapies: symptoms
and pathomechanism,” Current Opinion in Pharmacology,
vol. 29, pp. 97–103, 2016.
[5] T. Langbaum and T. J. Smith, “Time to study metastatic-
cancer survivorship,” The New England Journal of Medicine,
vol. 380, no. 14, pp. 1300–1302, 2019.
[6] W. Y. Cheung, M. S. Bayliss, M. K. White et al., “Humanistic
burden of disease for patients with advanced melanoma in
Canada,” Supportive Care in Cancer, vol. 26, no. 6, pp. 1985–
1991, 2018.
[7] J. McLoone, K. Watts, S. Menzies, B. Meiser, P. Butow, and
N. Kasparian, “When the risks are high: psychological adjust-
ment among melanoma survivors at high risk of developing
new primary disease,” Qualitative Health Research, vol. 22,
no. 8, pp. 1102–1113, 2012.
[8] O. Palesh, A. Aldridge-Gerry, K. Bugos et al., “Health behav-
iors and needs of melanoma survivors,” Supportive Care in
Cancer, vol. 22, no. 11, pp. 2973–2980, 2014.
[9] G. Abbey, S. B. N. Thompson, T. Hickish, and D. Heathcote,
“A meta-analysis of prevalence rates and moderating factors
for cancer-related post-traumatic stress disorder,” Psycho-
Oncology, vol. 24, no. 4, pp. 371–381, 2015.
[10] J. Dunn, M. Watson, J. F. Aitken, and M. K. Hyde, “Systematic
review of psychosocial outcomes for patients with advanced
melanoma,” Psycho-Oncology, vol. 26, no. 11, pp. 1722–1731,
2017.
[11] J. Ventura, R. P. Liberman, M. F. Green, A. Shaner, and
J. Mintz, “Training and quality assurance with the Structured
Clinical Interview for DSM-IV (SCID-I/P),” Psychiatry
Research, vol. 79, no. 2, pp. 163–173, 1998.
[12] N. K. Aaronson, S. Ahmedzai, B. Bergman et al., “The Euro-
pean Organization for Research and Treatment of Cancer
QLQ-C30: a quality-of-life instrument for use in international
clinical trials in oncology,” Journal of the National Cancer
Institute, vol. 85, no. 5, pp. 365–376, 1993.
[13] K. Cocks, M. T. King, G. Velikova et al., “Evidence-based
guidelines for interpreting change scores for the European
Organisation for the Research and Treatment of Cancer Qual-
ity of Life Questionnaire Core 30,” European Journal of Can-
cer, vol. 48, no. 11, pp. 1713–1721, 2012.
[14] J. M. Giesinger, F. L. C. Loth, N. K. Aaronson et al., “Thresholds
for clinical importance were established to improve interpreta-
tion of the EORTC QLQ-C30 in clinical practice and research,”
Journal of Clinical Epidemiology, vol. 118, pp. 1–8, 2020.
[15] A. S. Zigmond and R. P. Snaith, “The hospital anxiety and
depression scale,” Acta Psychiatrica Scandinavica, vol. 67,
no. 6, pp. 361–370, 1983.
[16] P. Spinhoven, J. Ormel, P. P. A. Sloekers, G. I. J. M. Kempen,
a.e.m. speckens, and A. M. V. hemert, “A validation study of
the Hospital Anxiety and Depression Scale (HADS) in differ-
ent groups of Dutch subjects,” Psychological Medicine,
vol. 27, no. 2, pp. 363–370, 1997.
[17] C. Bocerean and E. Dupret, “A validation study of the Hospital
Anxiety and Depression Scale (HADS) in a large sample of
French employees,” BMC Psychiatry, vol. 14, no. 1, p. 354,
2014.
[18] L. Castelli, L. Binaschi, P. Caldera, A. Mussa, and R. Torta,
“Fast screening of depression in cancer patients: the effective-
ness of the HADS,” European Journal of Cancer Care,
vol. 20, no. 4, pp. 528–533, 2011.
[19] L. B. Krupp, N. G. LaRocca, J. Muir-Nash, and A. D. Steinberg,
“The fatigue severity scale. Application to patients with multi-
ple sclerosis and systemic lupus erythematosus,” Archives of
Neurology, vol. 46, no. 10, pp. 1121–1123, 1989.
[20] M. Debouverie, S. Pittion, F. Guillemin, and H. Vespignani,
“Fatigue scales used in multiple sclerosis,” Revista de Neurolo-
gía, vol. 158, no. 11, pp. 1139–1143, 2002.
[21] M. B. Rietberg, E. E. H. vanWegen, and G. Kwakkel, “Measur-
ing fatigue in patients with multiple sclerosis: reproducibility,
responsiveness and concurrent validity of three Dutch self-
report questionnaires,” Disability and Rehabilitation, vol. 32,
no. 22, pp. 1870–1876, 2010.
[22] D. E. Broadbent, P. F. Cooper, P. FitzGerald, and K. R. Parkes,
“The Cognitive Failures Questionnaire (CFQ) and its corre-
lates,” The British Journal of Clinical Psychology, vol. 21,
no. 1, pp. 1–16, 1982.
10 Journal of Immunology Research
[23] R. W. H. M. Ponds, M. Van Boxtel, and J. Jolles, “De Cognitive
Failure Questionnaire als maat voor subjectief cognitief func-
tioneren,” Tijdschrift voor neuropsychologie, vol. 2, pp. 37–45,
2006.
[24] Carré, “Everyday life psychopathologie: validation of a new
cognitve failure's questionnaire,” Psychologie française,
vol. 59, no. 2, pp. 167–182, 2014.
[25] J. Vardy, K. Wong, Q. L. Yi et al., “Assessing cognitive function
in cancer patients,” Supportive Care in Cancer, vol. 14, no. 11,
pp. 1111–1118, 2006.
[26] L. Cogstate, Cogstate pediatric and adult normative data, Cog-
state Ltd: New Haven, CT, 2017.
[27] J. S. Wefel, J. Vardy, T. Ahles, and S. B. Schagen, “International
Cognition and Cancer Task Force recommendations to har-
monise studies of cognitive function in patients with cancer,”
The Lancet Oncology, vol. 12, no. 7, pp. 703–708, 2011.
[28] S. Nolte, G. Liegl, M. A. Petersen et al., “General population
normative data for the EORTC QLQ-C30 health-related qual-
ity of life questionnaire based on 15,386 persons across 13
European countries, Canada and the Unites States,” European
Journal of Cancer, vol. 107, pp. 153–163, 2019.
[29] S. Wilgenhof and B. Neyns, “Anti-CTLA-4 antibody-induced
Guillain–Barré syndrome in a melanoma patient,” Annals of
Oncology, vol. 22, no. 4, pp. 991–993, 2011.
[30] F. Bartels, T. Stronisch, K. Farmer, K. Rentzsch, F. Kiecker, and
C. Finke, “Neuronal autoantibodies associated with cognitive
impairment in melanoma patients,” Annals of Oncology,
vol. 30, no. 5, pp. 823–829, 2019.
[31] A. Rogiers, C. Leys, J. De Cremer et al., “Health-related quality
of life, emotional burden, and neurocognitive function in the
first generation of metastatic melanoma survivors treated with
pembrolizumab: a longitudinal pilot study,” Supportive Care in
Cancer, vol. 28, no. 7, pp. 3267–3278, 2020.
[32] G. J. McGinnis and J. Raber, “CNS side effects of immune
checkpoint inhibitors: preclinical models, genetics and multi-
modality therapy,” Immunotherapy, vol. 9, no. 11, pp. 929–
941, 2017.
[33] M. Miyajima, B. Zhang, Y. Sugiura et al., “Metabolic shift
induced by systemic activation of T cells in PD-1-deficient
mice perturbs brain monoamines and emotional behavior,”
Nature Immunology, vol. 18, no. 12, pp. 1342–1352, 2017.
[34] J. W.-L. Eng, K. M. Kokolus, C. B. Reed, B. L. Hylander, W. W.
Ma, and E. A. Repasky, “A nervous tumor microenvironment:
the impact of adrenergic stress on cancer cells, immunosup-
pression, and immunotherapeutic response,” Cancer Immu-
nology, Immunotherapy, vol. 63, no. 11, pp. 1115–1128, 2014.
[35] D. Levy, H. M. Dhillon, A. Lomax et al., “Certainty within
uncertainty: a qualitative study of the experience of metastatic
melanoma patients undergoing pembrolizumab immunother-
apy,” Supportive Care in Cancer, vol. 27, no. 5, pp. 1845–1852,
2019.
[36] E. E. Hahn, R. D. Hays, K. L. Kahn, M. S. Litwin, and P. A.
Ganz, “Post-traumatic stress symptoms in cancer survivors:
relationship to the impact of cancer scale and other associated
risk factors,” Psycho-Oncology, vol. 24, no. 6, pp. 643–652,
2015.
[37] A. Hinz, C. Finck Barboza, M. Zenger, S. Singer,
T. Schwalenberg, and J. U. Stolzenburg, “Response shift in
the assessment of anxiety, depression and perceived health in
urologic cancer patients: an individual perspective,” European
Journal of Cancer Care, vol. 20, no. 5, pp. 601–609, 2011.
[38] A. H. Boekhout, A. Rogiers, K. Jóźwiak et al., “Health-related
quality of life of advanced melanoma survivors treated with
CTLA-4 immune checkpoint inhibition: A matched cohort
study,” Annals of Oncology, vol. 30, pp. v668–v669, 2019.
[39] A. O’Reilly, P. Hughes, J. Mann et al., “An immunotherapy
survivor population: health-related quality of life and toxicity
in patients with metastatic melanoma treated with immune
checkpoint inhibitors,” Supportive Care in Cancer, vol. 28,
no. 2, pp. 561–570, 2020.
[40] D. Schadendorf, F. S. Hodi, C. Robert et al., “Pooled analysis of
long-term survival data from phase II and phase III trials of
ipilimumab in unresectable or metastatic melanoma,” Journal
of Clinical Oncology, vol. 33, no. 17, pp. 1889–1894, 2015.
[41] M. Maio, J. J. Grob, S. Aamdal et al., “Five-year survival rates
for treatment-naive patients with advanced melanoma who
received ipilimumab plus dacarbazine in a phase III trial,”
Journal of Clinical Oncology, vol. 33, no. 10, pp. 1191–1196,
2015.
11Journal of Immunology Research
